nintedanib sold brand names ofev vargatef oral medication used treatment idiopathic pulmonary fibrosis along medications types nonsmallcell lung march approved use united states treat chronic fibrosing scarring interstitial lung diseases ild progressive phenotype first treatment group fibrosing lung diseases worsen time approved us food drug administration common side effects include abdominal pain vomiting small molecule tyrosinekinase inhibitor targeting vascular endothelial growth factor receptor fibroblast growth factor receptor platelet derived growth factor ofev developed boehringer ingelheim received us food drug administration fda approval use idiopathic pulmonary fibrosis one two drugs available treating ipf numerous studies since demonstrated effectiveness slowing progressive terminal lung nintedanib used treatment idiopathic pulmonary shown slow decrease forced vital also improves peoples quality nintedanib improve survival people interferes processes like fibroblast proliferation differentiation laying extracellular national institute health care excellence nice recommends nintedanib cases ipf fvc predicted nice recommends discontinuation therapy persons fvc decreases period indicating disease progression despite also used combination docetaxel secondline treatment adult patients locally advanced metastatic locally recurring nonsmall cell lung cancer adenocarcinoma unclear combination compares second line agents comparisons done nintedanib contraindicated patients known hypersensitivity nintedanib peanut nintedanib tested patients moderate severe impairment liver function given drug metabolised liver may safe nintedanib used geriatric population without dose modifications studied paediatric populations hence given patients years age also contraindicated common side effects noted nintedanib include anorexia nausea vomiting diarrhea abdominal pain gastrointestinal perforation weight loss arterial thromboembolism including myocardial infarction bleeding hypothyroidism elevated liver enzymes headache gastrointestinal side effects decreased nintedanib coadministered side effects observed nintedanib worse higher dose reason subsequent trials used equally clinically effective lower nintedanib competitively inhibits nonreceptor tyrosine kinases nrtks receptor tyrosine kinases rtks nrtk targets nintedanib include lck lyn src rtk targets nintedanib include plateletderived growth factor receptor pdgfr α β fibroblast growth factor receptor fgfr vascular endothelial growth factor receptor vegfr use ipf predicated inhibition pdgfr fgfr vegfr increase fibroblast proliferation migration small percentage orally taken nintedanib absorbed gut partially due transport proteins pglycoprotein moving substance back lumen combined high firstpass effect results oral bioavailability mg drug reaches peak plasma levels hours oral intake form soft gelatin nintedanib mainly inactivated esterases cleave methyl ester resulting free carboxylic acid form glucuronidated uridinediphosphateglucuronosyltransferases excreted mostly via bile faeces relevant cytochrome mediated metabolism nintedanib substrate transporter pglycoprotein moves absorbed substance back guts lumen pglycoprotein inhibitor ketoconazole known increase blood plasma levels nintedanib factor inhibitors erythromycin ciclosporin expected similar effect hand pglycoprotein inducer rifampicin cuts nintedanib plasma levels half inducers carbamazepine phenytoin st johns wort probably lower plasma levels drug used form salt ethanesulfonic acid salt nintedanib esilate yellow crystalline solid melts poor solubility water somewhat better solubility dimethyl sulfoxide nintedanib approved idiopathic pulmonary fibrosis october united states food drug administration received positive opinion european medicines agency november approved european union january also approved canada japan switzerland verification two replicate randomized clinical trials evaluated efficacy safety nintedanib treatment idiopathic pulmonary primary endpoint study effect lung function measured forced vital capacity total patients treated either mg nintedanib placebo evaluated weeks end observation period nintedanib reduced decline forced vital study diarrhoea common adverse event higher nintedanib group compared placebo nintedanib granted orphan drug designation us fda treatment idiopathic pulmonary fibrosis june october nintedanib approved combination therapy nonsmallcell lung cancer european union approved indication parts nintedanib granted orphan drug designation us fda treatment systemic sclerosis including associated interstitial lung disease july september drug granted priority review designation fda approved us september slow rate decline pulmonary function patients systemic sclerosis associated interstitial lung disease first fdaapproved treatment rare lung effectiveness nintedanib treat sscild studied randomized doubleblind placebocontrolled trial subjects ages subjects received treatment weeks subjects treated primary test efficacy measured forced vital capacity fvc measure lung function defined amount air forcibly exhaled lungs taking deepest breath took nintedanib less lung function decline compared overall safety profile observed nintedanib treatment group consistent known safety profile frequent serious adverse event reported subjects treated nintedanib pneumonia nintedanib vs adverse reactions leading permanent dose reductions reported nintedanibtreated subjects compared placebotreated diarrhea frequent adverse reaction led permanent dose reduction subjects treated safety effectiveness nintedanib treat chronic fibrosing interstitial lung diseases progressive phenotype adults evaluated randomized doubleblind placebocontrolled study mean age subjects years subjects male primary test effectiveness forced vital capacity measure lung defined amount air forcibly exhaled lungs taking deepest breath period subjects received either milligrams nintedanib twice day weeks people received nintedanib less lung function decline compared us food drug administration fda granted nintedanib priority review designation breakthrough therapy fda granted approval ofev boehringer ingelheim pharmaceuticals boehringer using brand name ofev marketing nintedanib idiopathic pulmonary fibrosis vargatef marketing medication lung nintedanib testedwhen several phase iii clinical trials cancer angiogenesis inhibitors nintedanib may effective range solid tumour types including lung ovarian metastatic bowel liver brain cancermedical citation needed currentwhen phase ii trials investigating effect nintedanib patients bladder cancer metastatic bowel cancer liver cancer brain tumour glioblastoma phase iii trial completed investigated use nintedanib combination carboplatin paclitaxel first line treatment patients ovarian httpsenwikipediaorgwikinintedanib